Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 9/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 5/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.39 |
| ▸ | TYK2 | P29597 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136733 | 1.00 | SRC (0.40) | SRCFLT3ITKJAK2CDK2 | |
| SCHEMBL1136841 | 0.90 | ABCB1 (0.43) | JAK2CDK2CDK9ALKCDK4 | |
| SCHEMBL1136839 | 0.90 | ABCB1 (0.43) | JAK2CDK2CDK9ALKCDK4 | |
| SCHEMBL4790282 | 0.87 | JAK2 (0.35) | SRCFLT3ITKJAK2ALK | |
| SCHEMBL4790283 | 0.87 | JAK2 (0.35) | SRCFLT3ITKJAK2ALK | |
| SCHEMBL1136704 | 0.78 | CYP17A1 (0.41) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL1136702 | 0.78 | CYP17A1 (0.41) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL3000928 | 0.72 | MAOB (0.38) | ALKCYP17A1CYP21A2CYP11B1CYP3A4 | |
| SCHEMBL3000938 | 0.72 | MAOB (0.38) | ALKCYP17A1CYP21A2CYP11B1CYP3A4 | |
| SCHEMBL12864586 | 0.70 | FLT3 (0.64) | SRCFLT3ITKJAK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919905-B1 | 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECPTOR TYROSINE KINASES | VERTEX PHARMA (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7786120-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1919905-A2 | 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECPTOR TYROSINE KINASES | Vertex Pharmaceuticals Incorporated (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20070185125-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-09 | — | — | US | disclosed |
| WO-2007027528-A2 | 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-.RECEPTOR TYROSINE KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185125-A1 | Pyridones useful as inhibitors of kinases | MAP3K20, MAP3K6, MAP3K5 | SRC 369/4885FLT3 416/4885ITK 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.